<生产厂家价格>

马来酸伊索拉定

马来酸伊索拉定用途

Irsogladine马来酸盐是PDE4抑制剂和毒蕈碱乙酰胆碱受体结合剂。

马来酸伊索拉定名称

[ CAS 号 ]:
84504-69-8

[ 中文名 ]:
马来酸伊索拉定

[ 英文名 ]:
Irsogladine Maleate

[中文别名 ]:

马来酸依索拉啶

[英文别名 ]:

MN 1695 {Maleate}
MFCD00873566
Irsogladine maleate

马来酸伊索拉定生物活性

[ 描述 ]:

Irsogladine马来酸盐是PDE4抑制剂和毒蕈碱乙酰胆碱受体结合剂。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 由mAChR

信号通路 >> 神经信号通路 >> mAChR

信号通路 >> 代谢酶/蛋白酶 >> 磷酸二酯酶(PDE)

研究领域 >> 炎症/免疫

[参考文献]

[1]. Ren, C.J., et al., Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res, 1998. 77(2): p. 126-31.

[2]. Kawasaki, Y., et al., Irsogladine malate up-regulates gap junctional intercellular communication between pancreatic cancer cells via PKA pathway. Pancreas, 2002. 25(4): p. 373-7.

[3]. Kyoi, T., et al., Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Life Sci, 2004. 75(15): p. 1833-42.

[相关活性小分子]

马来酸伊索拉定物理化学性质

[ 沸点 ]:
552.2ºC at 760 mmHg

[ 熔点 ]:
181-182°C

[ 分子式 ]:
C₁₃H₁₁Cl₂N₅O₄

[ 分子量 ]:
372.164

[ 闪点 ]:
287.8ºC

[ 精确质量 ]:
371.018799

[ PSA ]:
165.31000

[ LogP ]:
2.88400

[ 外观性状 ]:
白色-类白色晶体-粉末

[ 储存条件 ]:
Desiccate at RT

马来酸伊索拉定MSDS

详细MSDS(安全技术说明书)

马来酸伊索拉定毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: XY5930000

CHEMICAL NAME :: s-Triazine, 2,4-diamino-6-(2,5-dichlorophenyl)-, maleate

CAS REGISTRY NUMBER :: 84504-69-8

LAST UPDATED :: 199703

DATA ITEMS CITED :: 12

MOLECULAR FORMULA :: C9-H7-Cl2-N5.C4-H4-O4

MOLECULAR WEIGHT :: 372.19

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2898 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #114907

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 495 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4657907

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1524 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 34,474,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5697 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 34,474,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 775 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 34,474,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2841 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 34,474,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >250 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 20,228,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 100 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - lacrimation Behavioral - ataxia Gastrointestinal - nausea or vomiting

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 32,861,1986

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - lacrimation Behavioral - altered sleep time (including change in righting reflex) Gastrointestinal - changes in structure or function of salivary glands

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 32,861,1986 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2310 mg/kg

SEX/DURATION :: male 11 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 32,623,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 810 mg/kg

SEX/DURATION :: female 17-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 32,657,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 390 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 33,121,1987

马来酸伊索拉定安全信息

[ 危险品运输编码 ]:
NONH for all modes of transport

[ RTECS号 ]:
XY5930000

[ 海关编码 ]:
2933699090

马来酸伊索拉定制备

1. 2,5-二氯苯乙酮的制备

在反应瓶中加入对二氯苯14.7g(0.1mol)和无水三氯化铝26.7g(0.2mol),搅拌热熔融,于室温或60~70ºC滴加氯乙酰8.6g(0.1mol),加毕#加热至115ºC,在该温度下搅拌反应6h.冷却后倾入100ml,冰水中,分出有机层,水层用氯仿提取,合并有机层用无水Na2SO4干燥,过滤,滤液蒸除溶剂,剩余液减压分馏,取152~154ºC/1.3kPa馏分,得浅黄色油状液体馏分,得浅黄色油状液体2,5-二氯苯乙酮15.7g,收率83.1%.

2. 2,5-二氯苯甲酸的制备

在反应瓶中加入NaOH40g(0.1mol)和水200ml,搅拌溶解,冷却至0~5ºC,滴加液溴32g(0.2mol),再滴加2.5-二氯苯乙酮18.9g(0.1mol),滴毕,室温搅拌2h.分去溴仿层,水层用盐酸调pH至3,过滤,水洗,干燥得浅黄色固体,用乙醇重结晶,得白色结晶2,5-二氯苯甲酸14.9g,收率78.9%,mp154~156ºC.

3. 2,5-二氯苄腈的制备

在反应瓶中加入2,5-二氯苯甲酸19.1g(0.1mol)、对甲苯磺酰胺34.2g(0.2mol)和五氯化磷20.9g(0.1mol),搅拌均匀后加热至220ºC,在该温度下反应1h.冷却,加入热水100ml,析晶后,过滤,水洗,干燥得黄色固体,用乙醇重结晶,得白色结晶2,5-二氯苄腈14.8g,收率86.3%,mp128~130ºC.

4. 伊索拉定的制备

在反应瓶中加入2,5-二氯苄腈17.2g(0.1mol)、氰基胍12.6g(0.15mol)和KOH5.6g(0.1mol),再加入羟丙基甲醚100ml,搅拌回流3h.冷却,倾入300ml水中,过滤,水洗,干燥得淡黄色固体,用乙醇重结晶得白色固体(结晶)伊索拉定11.4g,收率66.3%,mp268~269ºC.

5. 马来酸伊索拉定的合成

在反应瓶中加入伊索拉定25.6g(0.1mol)、马来酸11.6g(0.1mol)和羟丙基甲醚200ml#搅拌回流1h.冷却,过滤,水洗,干燥得淡黄色固体,用乙醇重结晶得白色结晶马来酸伊索拉定31.0g,收率83.3%,mp183~185ºC(分解).

马来酸伊索拉定海关

[ 海关编码 ]: 2933699090

[ 中文概述 ]:
2933699090 其他结构上含非稠合三嗪环化合物. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:6.5% 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933699090 other compounds containing an unfused triazine ring (whether or not hydrogenated) in the structure。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:20.0%